Behavioral Tolerance Did Not End Every Adverse Finding in High-Dose Animal Experiments

A reduction in an early drug response did not mean that every adverse effect disappeared during repeated exposure. A historical chapter described animal experiments in which tolerance to initial depression preceded a different pattern of behavioral and pathological findings.

The observed pattern changed over time

Nahas summarized repeated-administration studies using high daily cannabinoid or cannabis-extract doses in rats and monkeys. Early generalized depression diminished, while later observations included hyperactivity and other adverse findings.

The chapter explicitly acknowledged that the doses were far out of proportion to heavy human cannabis consumption. That qualification limits direct application to ordinary human exposure.

Tolerance is defined by a particular response

Becoming less responsive on one behavioral measure does not demonstrate protection against a different endpoint. Adaptation to initial depression and later tissue or behavioral abnormalities are not logically incompatible.

The experiments therefore should not be reduced to either complete recovery or uniform worsening. Their interpretation depends on which response was measured and when it was measured.

Do not translate extreme regimens into ordinary-use risks

The chapter’s summaries do not establish the frequency of these findings in people or a comparable human regimen. Species, preparation and exposure intensity remain central.

The supported methodological point is narrower: evidence of tolerance needs an endpoint, and it cannot serve as a general certificate of safety. Conversely, adverse findings under an extreme animal regimen cannot by themselves quantify risk from a different human exposure.

Related: Interpreting cannabis tolerance evidence.

Research cited

Gabriel G. Nahas. Marihuana: Toxicity and Tolerance. Historical book chapter, pp. 16–36.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Randomized CBD Burnout Study Was Open-Label and Did Not Test Antiviral Efficacy

Random assignment did not make a CBD burnout study blinded, and improvement in pandemic-related distress did not demonstrate treatment of viral infection. A supplied review’s account of the BONSAI study requires both distinctions. The clinical target was burnout and emotional distress The review describes a prospective, randomized, open-label study of…

Spread the love

Read Article: A Randomized CBD Burnout Study Was Open-Label and Did Not Test Antiviral Efficacy

Smoking-Related Lung Observations Did Not Isolate THC as the Cause

Lung findings in people who smoked cannabis cannot automatically be attributed to THC alone. A historical chapter recognized that smoke contains multiple plant constituents and combustion products, making component-specific claims more difficult than simply identifying cannabis use. The chapter assembled different kinds of evidence Nahas discussed clinical reports of respiratory…

Spread the love

Read Article: Smoking-Related Lung Observations Did Not Isolate THC as the Cause

Historical Developmental-Toxicity Reports Used Different Cannabis Preparations

Historical developmental-toxicity findings varied across cannabis extracts, purified cannabinoids, animal species and exposure procedures. A chapter describing those experiments does not support treating every result as a controlled comparison of the same substance. The chapter described conflicting animal observations Nahas summarized developmental findings after cannabis resin or concentrated extracts and…

Spread the love

Read Article: Historical Developmental-Toxicity Reports Used Different Cannabis Preparations

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us